AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT00528645 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

NIH

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer
Lung Metastases
Malignant Pleural Effusion
Recurrent Small Cell Lung Cancer

Interventions

DRUG: saracatinib

Sponsor

National Cancer Institute (NCI)